# This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

> **NCT03448406** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 315 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03448406
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2019-10-04
- **Final completion:** 2019-10-09
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2020-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448406, "This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03448406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*